Uppsala Monitoring Centre

Recent papers from Uppsala Monitoring Centre

1. Toward a Framework for Case Identification in Pharmacovigilance: Not All Reports are Created EqualDrug Safety · 2026
2. The Value of Time-to-Onset for Signal Validation: Experience from the Reporting of COVID-19 Vaccines and Glomerular Diseases in VigiBaseDrug Safety · 2026
3. Medication persistence and mortality in ST-elevation myocardial infarction patients with and without standard modifiable risk factors: a SWEDEHEART registry studyEuropean Journal of Preventive Cardiology · 2026
4. Cardiovascular Outcomes in a SELECT ‐Like Obesity Cohort: Real‐World Insights From the Swedish AROS DatabaseDiabetes Obesity and Metabolism · 2026
5. A ‘One Health’ cross-sectional analysis of reports of potential antibiotic resistance cases in international pharmacovigilance databasesFrontiers in Public Health · 2026
6. Underdiagnosed and Undertreated: Obesity and Its Cardiometabolic Burden in Swedish Clinical Practice—Insights From the AROS DatabaseDiabetes Obesity and Metabolism · 2026
7. A comparison of antibiotic resistance reports in pharmacovigilance databases and conventional surveillance across “One Health”Frontiers in Public Health · 2026
8. Reply to “A Comment about AI Methods that May Help Advance Pharmacovigilance”Clinical Pharmacology & Therapeutics · 2026
9. International Medicinal Product Information Documents: A Quantitative Content Analysis of Instructions for Preventing, Mitigating, and Monitoring Adverse Drug ReactionsDrug Safety · 2026
10. Critical Appraisal of Artificial Intelligence for Rare-Event Recognition: Principles and Pharmacovigilance Case StudiesDrug Safety · 2026
11. VigiBase: Resource Profile Update with a Summary of Global Patterns and Trends in Adverse Event Reports for Medicines and VaccinesDrug Safety · 2026
12. The Rising Misuse of Pharmacovigilance Reporting Systems: A Threat to Evidence‐Based MedicineClinical Pharmacology & Therapeutics · 2025
13. Causal Inference Tools for Pharmacovigilance: Using Causal Graphs to Identify and Address Biases in Disproportionality AnalysisDrug Safety · 2025
14. Clinical assessment and acceptance criteria for continuous glucose monitoring (CGM) system performance: A proposed guideline by the IFCC Working Group on CGMClinica Chimica Acta · 2025
15. Recommendations to Enable Broader Use of Real‐World Evidence to Inform Decision‐Making Throughout Pharmacovigilance Signal ManagementPharmacoepidemiology and Drug Safety · 2025
16. Charting and Sidestepping the Pitfalls of Disproportionality AnalysisDrug Safety · 2025
17. Pharmacogenetics of metamizole-induced agranulocytosis: a systematic review and drug regulation implicationsFrontiers in Pharmacology · 2025
18. Advancing Global Harmonization: Implementing Global Dose Form Attributes for Medicinal Products IdentificationTherapeutic Innovation & Regulatory Science · 2025
19. Exploring the Reliability of Detecting Drug–Drug Interactions that Increase the Risk of Gestational Diabetes in Adverse Event Reporting SystemsDrug Safety · 2025
20. Spontaneous Reports of Adverse Reactions with Fatal Outcomes After COVID-19 Vaccination During the National Vaccination Campaign in SwedenClinical Drug Investigation · 2025